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Background:Wesought to evaluate and validate the 8th edition of theAJCC classification using a
multi-institutional cohort of patients with intrahepatic cholangiocarcinoma (ICC).
Methods:Patients undergoing curative-intent hepatic resection for ICCbetween1990 and 2015
at 14 major hepatobiliary centers were included and were staged according to 7th and 8th
editions AJCC criteria.
Results:A total of 1154 patients underwent liver resection for ICC. When patients were staged
using the AJCC 7th edition, T2a, T2b, and T4 patients had a higher hazard ratio (HR) of death
comparedwith T1 (T2a, HR1.43, P = 0.004; T2b,HR 1.99, P < 0.001; T4, HR 2.20, P < 0.001). T3
patients had ahigherHRof death comparedwithT1patients (HR1.30,P = 0.029) but lower than
T2a and T2b. According to AJCC 8th edition, T1b, T2, and T4 patients were at higher risk of
death comparedwithT1apatients (T1b,HR1.91,P < 0.001; T2,HR2.29,P < 0.001; T4,HR4.16,
P < 0.001). As in the AJCC 7th edition, AJCC 8th edition T3 patients had a higher HR of death
compared with T1 patients (HR 1.65, P = 0.001) but lower than T1b and T2. AJCC 8th edition.
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T-category performed slightly better than AJCC 7th edition with a C-index of 0.609 versus
0.590.
Conclusions: A staging system that perfectly discriminates between stages has not yet been
developed, but the AJCC 8th edition was able to better stratify the risk of death of Stage III and
T3 patients.
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1 | INTRODUCTION
Although intrahepatic cholangiocarcinoma (ICC) has historically been
considered a relatively uncommon disease, its incidence is increasing
worldwide. As a consequence, a growing body of evidence on factors
associated with long-term outcomes of ICC patients has emerged.1–8
The importance of ICC has been recently recognized by the American
Joint Committee on Cancer (AJCC) with the 7th edition of the AJCC
StagingManual incorporating a tumor-node-metastasis (TNM) staging
system for ICC distinct from hepatocellular carcinoma (HCC) and
extrahepatic bile duct malignancies.9 In the AJCC 7th edition,
T-category was based on three major prognostic factors including
tumor number, vascular invasion, and direct extrahepatic extension
derived from the work of Nathan et al.10 N-category was based on the
presence or absence of metastasis in one or more regional lymph
nodes; specifically, for a left-sided ICC, nodal disease in the common
bile duct, hepatic artery, portal vein, and cystic duct nodes, while for a
right-sided ICC, the nodal basins of interest were hilar, periduodenal,
and peripancreatic. The 7th edition of the AJCC staging system was
subsequently validated in several different cohorts.11–16 Over time,
however, several groups proposed modifications to the staging
system. For example, Igami et al advocated for replacing periductal
invasion with multiple tumors for T4 disease, as well as categorizing
nodal metastasis in the gastrohepatic lymph node basin as distant
metastasis.13
Recently, the 8th edition of the AJCC staging manual was
published.17 In this edition, ICC staging remained independent of the
staging systems for HCC and extrahepatic bile duct cholangiocarci-
nomas, yet mixed hepato-cholangio carcinomas and rare intrahepatic
primary neuroendocrine tumors were included in the staging system.
Importantly, the 8th edition of the AJCC staging system introduced
several notable changes to the T-category classification schema. In
particular, T1 disease has been modified to account for the prognostic
impact of tumor size (T1a, solitary tumor ≤5 cm vs. T1b, solitary tumor
>5 cm). T2 has been revised to reflect the equivalent prognostic effect
of tumor number and vascular invasion (T2, solitary tumor with
intrahepatic vascular invasion or multiple tumors, with or without
vascular invasion). In addition, T4 disease, which previously was based
on tumor growth pattern, has been excluded from the 8th edition.
Given the recent introduction of this new staging system, the
objective of the current study was to evaluate and validate the new
edition of the AJCC staging system using a large multi-institutional
cohort of patients with ICC.
2 | MATERIALS AND METHODS
2.1 | Patient demographic and clinical data
Patients undergoing curative-intent hepatic resection for ICCbetween
1990 and 2015 at 14 major hepatobiliary centers in the United States,
Europe, Australia, and Asia (Johns Hopkins Hospital, Baltimore, MD;
Stanford University, Stanford, CA; University of Virginia, Charlottes-
ville, VA; Emory University, Atlanta, GA; Fundeni Clinical Institute of
Digestive Disease, Bucharest, Romania; Curry Cabral Hospital, Lisbon,
Portugal; Ospedale San Raffaele, Milan, Italy; Royal Prince Alfred
Hospital, University of Sydney, Sydney, Australia; Eastern Hepato-
biliary Surgery Hospital, Shanghai, China; Beaujon Hospital, Clichy,
France; University of Ottawa, Ottawa, Ontario, Canada; Erasmus
University Medical Centre, Rotterdam, Netherlands; Yokohama City
University School of Medicine, Yokohama, Japan; University of
Verona, School of Medicine, Verona, Italy) were identified. Only
patientswith histologically confirmed ICCwere included. Patientswith
metastatic disease and those who underwent a R2 resection were
excluded. Patients who underwent a palliative operation, those who
underwent only ablation or intra-arterial therapy (IAT) were also
excluded. The Institutional Review Board of each institution approved
the study.
Standard patient demographic and clinicopathologic data were
collected including age, sex, American Society of Anesthesiologists
(ASA) classification and presence of cirrhosis. Serum level of
carcinoembryonic antigen (CEA) and Cancer Antigen (CA) 19-9
were also collected. Data regarding treatment were collected
including receipt of neoadjuvant chemotherapy, type of surgery,
and receipt of adjuvant treatments. Resection margin status was
classified as microscopically negative (R0) or microscopically positive
(R1). Tumor-specific characteristics including tumor size and
number, liver capsule involvement, histological grade, morphological
type, number of lymph nodes achieved, and number of metastatic
lymph nodes were included. Even if it can be difficult to determine
the local extent of disease on radiological imaging, the major
prognostic factors, including tumor size and number, vascular
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invasion, perforation of the visceral peritoneum, and regional lymph
node involvement, as defined by high-resolution cross-sectional
imaging, biopsy tissue and surgical pathology.17 Presence of
vascular/perineural/biliary invasion, and direct invasion of contigu-
ous organs were also recorded. Data on tumor stage were collected
according to both the 7th and the 8th edition AJCC staging
systems.9 Perioperative complications and mortality were consid-
ered within 90 days from the operation.18
2.2 | Statistical analysis
Continuous variables were summarized as medians with interquartile
ranges (IQR) while categorical variables were reported as whole
numbers and percentages. The outcome for survival analyses was
overall survival (OS), defined as the time interval between the date of
surgery and the date of death. Time was censored at the date of last
follow-up for living patients. OS estimates were calculated using the
Kaplan-Meier method. Cox proportional hazards models were used to
evaluate associations between tumor stage and OS. The coefficients
from theCoxmodelswere subsequently reported as hazard ratios (HR)
with corresponding 95% confidence intervals (CI). In order to assess
the performance of the 7th and the 8th edition AJCC staging systems,
the concordance index (C-index) was utilized.19 Standard errors, CI,
and P values for the C-index were computed by assuming asymptotic
normality.20,21
3 | RESULTS
3.1 | Clinicopathologic characteristics of the study
group
A total of 1154 patients underwent liver resection for ICC. The
majority of patients were male (n = 638, 55.3%) and median age
was 60.4 years old (IQR, 51.7-69.0; Table 1). Preoperatively,
median CA 19-9 and CEA were 49 U/mL (IQR, 16.9-218.0) and
2.4 ng/mL (IQR, 1.4-4.3), respectively. Cirrhosis, HBV, and HCV
infections were present in 118 (10.2%), 205 (17.8%), and 31
(2.7%) patients, respectively. The majority of patients had a single
ICC (n = 941, 81.5%) and median tumor size was 6 cm (IQR, 4.0-
8.5). Major vascular invasion was noted in 156 (13.5%) patients
and liver capsule involvement in 209 (18.1%) patients. The
majority of patients underwent a major hepatectomy (n = 708,
61.4%), whereas 289 (25.0%) patients underwent a minor
hepatectomy and 157 (13.6%) a wedge resection. ICC was well
differentiated in 147 (13.6%) patients, moderately differentiated
in 739 (68.9%), and poorly/un-differentiated in 188 (17.5%).
Surgical margins of the resected specimen were negative (R0) in
992 (87.2%) patients, while 146 (12.8%) patients were R1.
Lymph-vascular invasion was present in 356 (30.8%) patients and
perineural invasion in 215 (21.1%). Overall, 200 (17.3%) patients
had lymph nodes metastasis, while 315 (27.3%) patients had no
lymph node metastasis; lymphadenectomy was not performed in
639 (55.4%) patients.






















Mass-forming (MF) 941 (87.0)
Periductal-infiltrating (PI) 54 (4.9)
MF + PI 88 (8.1)
NA 71
Ca 19-9, median (IQR) 49 U/mL (16.9-218.0)
CEA, median (IQR) 2.4 ng/mL (1.4-4.3)
Type of surgery
Wedge resection 157 (13.6)
Minor hepatectomy 289 (25.0)
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3.2 | Comparison of AJCC 7th and 8th editions
T-categories
A total of 487 (42.2%) patients had a solitary ICC without vascular
invasion (T1 AJCC 7th ed.) while 207 (17.9%) and 123 (10.7%) patients
had a solitary ICCwith vascular invasion (T2a AJCC 7th ed.) or multiple
ICCwith or without vascular invasion (T2b AJCC 7th ed.), respectively.
There were 195 (16.9%) patients with ICC perforating the visceral
peritoneum or involving the local extra-hepatic structures by direct
invasion (T3 AJCC 7th ed.), while 142 (12.3%) patients had ICC with
periductal invasion (PI and MF + PI; T4 AJCC 7th ed.). When the AJCC
7th edition T-staging system was used, 5-year OS was 49.3% (95%
Confidence Interval, 43.4-54.9) in T1 patients, 35.7% (95% CI,
26.7-44.8) in T2a patients, 20.9% (95% CI, 12.4-31.0) in T2b patients,
42.5% (95% CI, 34.2-50.6) in T3 patients, and 25.5% (95% CI, 17.
3-34.4) in T4 patients (Table 2 and Fig. 1a).
A total of 249 (21.6%) patients had a solitary ICC without vascular
invasion measuring ≤5 cm (T1a AJCC 8th ed.) while 270 (23.4%)
patients had a solitary ICC without vascular invasion >5 cm (T1b AJCC
8th ed.). About one third of patients (n = 402; 34.8%) had a solitary ICC
with vascular invasion or multiple ICC with or without vascular
invasion (T2 AJCC 8th ed.). There were 167 (14.5%) patients with ICC
perforating the visceral peritoneum (T3 AJCC 8th ed.) and there were
66 (5.7%) with ICC involving local extra hepatic structures by direct
invasion (T4 AJCC 8th ed.). According to AJCC 8th edition, 5-year OS
was 60.8% (95% CI, 52.6-68.0) in T1a patients, 36.7% (95% CI, 29.2-
44.2) in T1b, 29.3% (95% CI, 23.3-35.5) in T2, 45.8% (95% CI, 36.6-
54.4) in T3, and 14.7% (95% CI, 6.4-26.5) in T4, respectively (Table 2
and Fig. 1b).
When patients were categorized using the AJCC 7th edition
T-category system, T2a, T2b, and T4 patients had a higher HR of
death compared with T1 (AJCC 7th ed., T2a vs. T1, HR 1.43 95% CI,
1.12-1.83 P = 0.004; T2b vs. T1, HR 1.99 95% CI, 1.52-2.59,
P < 0.001; T4 vs. T1, HR 2.20 95% CI, 1.72-2.82 P < 0.001; Fig. 1a).
Of note, T3 patients had a higher HR of death compared with T1
patients (AJCC 7th ed. T3 vs. T1, HR 1.30 95% CI, 1.03-1.66
P = 0.029) but lower than T2a and T2b patients. According to AJCC
8th edition, T1b, T2, and T4 patients were at higher risk of death
compared with T1a patients (AJCC 8th ed., T1b vs. T1a, HR 1.91
95% CI, 1.45-2.50 P < 0.001; T2 vs. T1a, HR 2.29 95% CI, 1.78-2.96,
P < 0.001; T4 vs. T1a, HR 4.16 95% CI, 2.92-5.94 P < 0.001; Fig. 1b).
As in the AJCC 7th edition, AJCC 8th edition. T3 patients had a
higher HR of death compared with T1 patients (AJCC 8th ed. T3 vs.
T1, HR 1.65 95% CI, 1.22-2.24 P = 0.001), but lower than T1b and
T2 patients.
A validation analysis was performed to compare the ability of the
two editions of AJCC T-staging systems to stratify patients based on
risk of death. AJCC 7th edition T-category had a C-index of 0.590
comparedwith a C-index of 0.609 for the AJCC 8th edition T-category
(Table 3).
3.3 | Comparison of AJCC 7th and 8th editions
According to the AJCC 7th edition, 93 (18.1%) patients were
classified as Stage I and had a 5-year OS of 58.8% (95% CI,
44.9-70.3; Table 4 and Fig. 2a). According to the AJCC 8th edition,
15 (5.1%) patients were classified as Stage Ia and 18 (6.1%) as Stage
Ib with a 5-year OS of 90.0% (95% CI, 47.3-98.5) and 50.6% (95% CI,
19.9-75.0), respectively (Fig. 2b). Based on the AJCC 7th edition,
110 (21.4%) patients were classified as Stage II with a 5-year OS of
38.8% (95% CI, 26.5-51.0), while 37 (12.5%) patients were classified
as Stage II according to the AJCC 8th edition with a 5-year OS of
55.1% (95% CI, 34.5-71.7). According to the AJCC 7th edition, 70
(13.6%) patients were classified as Stage III and had a 5-year OS of
39.7% (95% CI, 24.1-54.9); conversely, 22 (7.4%) and 204 (16.2%)
patients were defined as Stages IIIa and b according to the AJCC 8th
TABLE 1 (Continued)
Variables N (%)
Not present 998 (86.5)
Present 156 (13.5)
Lymph-vascular invasion















Not harvested 639 (55.4)
NA, not available.
TABLE 2 Comparison between the 7th and the 8th edition of the
AJCC T staging systems—Kaplan-Meier analysis
N = 1154 (%) 5-year (%) 95% CI
AJCC 7th ed. T-category
T1 487 (42.2) 49.3 43.4-54.9
T2a 207 (17.9) 35.7 26.7-44.8
T2b 123 (10.7) 20.9 12.4-31.0
T3 195 (16.9) 42.5 34.2-50.6
T4 142 (12.3) 25.5 17.3-34.4
AJCC 8th ed. T-category
T1a 249 (21.6) 60.8 52.6-68.0
T1b 270 (23.4) 36.7 29.2-44.2
T2 402 (34.8) 29.3 23.3-35.5
T3 167 (14.5) 45.8 36.6-54.4
T4 66 (5.7) 14.7 6.4-26.5
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edition, and had a 5-year OS of 49.7% (95% CI, 16.6-76.2) and
16.2% (95% CI, 9.5-24.5), respectively. Moreover, according to
AJCC 7th edition, 242 (46.9%) patients were classified in Stage IVa
with a 5-year OS of 18.4% (95% CI, 11.9-26.1).
ComparedwithAJCC7theditionStage I, patients inAJCC7thedition
Stages II and IVawereathigher riskofdeath (AJCC7thed., II vs. I,HR1.89,
95% CI, 1.17-3.06 P = 0.010; IVa vs. I, HR 3.63, 95% CI, 2.38-5.53
P < 0.001).Of note, AJCC7th edition Stage III patients had a higherHRof
death comparedwith Stage I patients (AJCC 7th ed. III vs. I, HR 1.69 95%
CI, 0.99-2.89P = 0.053) but lower thanStage II. ComparedwithAJCC8th
edition Stage I, patients in AJCC8th edition Stages Ib, II, IIIa, and IIIbwere
at higher risk of death (AJCC8th ed., Ib vs. Ia, HR 6.42, 95%CI, 0.77-53. 4
P = 0.085; II vs. Ia, HR 5.89, 95% CI, 0.77-45.0, P = 0.088; IIIa vs. Ia, HR
7.39 95%CI, 0.91-60.2 P = 0.061; IIIb vs. Ia, HR 16.4, 95%CI, 2.29-117.4
P = 0.005;Table5).Ofnote,AJCC8theditionStages Ib, II, and IIIapatients
had a higher HR of death compared with Stage Ia patients, but the
difference was not statistically significant.
A validation analysis was performed to compare the two
editions of the AJCC staging system. AJCC 7th edition had a
C-index of 0.637 compared with a C-index of 0.607 of the AJCC 8th
edition (Table 5).
3.4 | Comparison of AJCC 7th and 8th editions
including patients with lymph node staging assessed
by radiological imaging
Given the high number of patients who did not undergo
lymphadenectomy (Nx), we performed a sensitivity analysis. To
further assess the performance of the 7th and 8th staging systems
based on both preoperative radiological imaging and the pathologi-
cal specimen. The total number of patients included in the sub-set
analysis was 932. According to the AJCC 7th edition, 356 (38.2%)
patients were classified as Stage I and had a 5-year OS of 55.0%
(95% CI, 48.0-61.4; Table S1). According to the AJCC 8th edition,
178 (19.1%) patients were classified as Stage Ia and 196 (21.0%) as
Stage Ib with a 5-year OS of 69.2% (95% CI, 59.8-76.8), and 40.9%
(95% CI, 31.6-49.9), respectively. Based on the AJCC 7th edition,
197 (21.2%) patients were classified as Stage II with a 5-year OS of
36.8% (95% CI, 27.7-45.8), while 222 (23.8%) patients were
classified as Stage II according to the AJCC 8th edition with a
5-year OS of 35.9% (95% CI, 27.2-44.7). According to the AJCC 7th
edition classification, 128 (13.7%) patients were classified as Stage
III and had a 5-year OS of 54.4% (95% CI, 43.6-64.1); conversely,
FIGURE 1 A) Kaplan-Meier overall survival curves stratified by AJCC 7th T-category. B) Kaplan-Meier overall survival curves stratified by
AJCC 8th T-category
TABLE 3 Comparison between the 7th and the 8th edition of the
AJCC T staging systems—Validation




T1 – – –
T2a 1.43 1.12-1.83 0.004
T2b 1.99 1.52-2.59 <0.001
T3 1.30 1.03-1.66 0.029




T1a – – –
T1b 1.91 1.45-2.50 <0.001
T2 2.29 1.78-2.96 <0.001
T3 1.65 1.22-2.24 0.001
T4 4.16 2.92-5.94 <0.001
TABLE 4 Comparison between the 7th and the 8th edition of the
AJCC staging systems—Kaplan-Meier analysis
N (%) 5-year (%) 95% CI
AJCC 7th editiona
I 93 (18.1) 58.8 44.9-70.3
II 110 (21.4) 38.8 26.5-51.0
III 70 (13.6) 39.7 24.1-54.9
IVa 242 (46.9) 18.4 11.9-26.1
AJCC 8th editionb
Ia 15 (5.1) 90.0 47.3-98.5
Ib 18 (6.1) 50.6 19.9-75.0
II 37 (12.5) 55.1 34.5-71.7
IIIa 22 (7.4) 49.7 16.6-76.2
IIIb 204 (68.9) 16.2 9.5-24.5
aN = 515.
bN = 296.
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109 (11.7%) and 227 (24.4%) patients were defined as Stages IIIa
and b according to the AJCC 8th edition edition classification and
had a 5-year OS of 60.0% (95% CI, 48.4-69.8) and 16.3% (95% CI,
9.9-24.0), respectively. Moreover, according to AJCC 7th edition,
251 (26.9%) patients were classified in Stage IVa with a 5-year OS of
19.5% (95% CI, 12.7-27.2).
Compared with AJCC 7th edition Stage I, patients in AJCC 7th
edition Stages II and IVa were at higher risk of death (AJCC 7th ed.,
II vs. I, HR 1.49, 95% CI, 1.14-1.97 P = 0.003; IVa vs. I, HR 2.63,
95% CI, 2.07-3.34 P < 0.001). Conversely, AJCC 7th edition Stage
III patients did not have a higher HR of death compared with Stage
I patients (AJCC 7th ed. III vs. I, HR 1.05 95% CI, 0.76-1.45
P = 0.78). Compared with AJCC 8th edition Stage I, patients in
AJCC 8th edition Stages Ib, II, and IIIb were at higher risk of death
(AJCC 8th ed., Ib vs. Ia, HR 2.32, 95% CI, 1.61-3.34 P < 0.001; II vs.
Ia, HR 2.41, 95% CI, 1.69-3.45, P < 0.001; IIIb vs. Ia, HR 4.53, 95%
CI, 3.22-6.39 P < 0.001; Table S2). Of note, AJCC 8th edition Stage
IIIa patients had a higher HR of death compared with Stage Ib
patients (AJCC 8th ed. IIIa vs. Ib, HR 1.49 95% CI, 0.97-2.30
P = 0.07), but lower than Stages Ib and II.
A validation analysis was performed to compare the two
editions of the AJCC staging system. AJCC 7th edition had a
C-index of 0.642 compared with a C-index of 0.667 of the AJCC 8th
edition (P = 0.98; Table S2).
4 | DISCUSSION
Staging of ICC has historically mirrored the staging system for HCC and
extrahepatic cholangiocarcinoma, largely due to the fact that ICC is a
relatively uncommon disease. However, over the last decade there has
beenan increased recognitionof ICCasadistinctclinical entity. Following
the introduction of the first unique staging system for ICC in the 7th
edition AJCC staging manual, the staging of ICC has continued to
evolve.11–16Several staging systemshavebeenproposed; forexample, in
addition to the AJCC staging system in Western Countries, the Liver
Cancer Study Group of Japan (LCSGJ) has proposed a distinct staging
system that is used in many Eastern Countries.9,22 In the newly released
8th edition of the AJCC staging manual, while ICC remained a separate
unique staging system, several new revisions to the staging of ICC were
introduced. Specifically, in the8thedition, T1disease has been revised to
include tumor size (≤5 cm vs. >5 cm); T2 was also modified to reflect an
equivalentprognostic valueofvascular invasionandmultifocaldisease. In
addition, 7theditionT4disease that described tumor growthpatternwas
excluded from staging with T4 disease now defined as involving local
extrahepatic structures by direct invasion. Thecurrent study is important
because it is one of the first reports to validate the newly proposed 8th
edition ICC stating. In addition, unlikemany other small single institution
case series, the current study utilized a large, international, multi-
institutional cohort of patients undergoing curative-intent surgery for
ICC to evaluate the 8th edition of the AJCC staging system.
In examining the T categories, the AJCC 8th edition discriminated
prognosis with variable effectiveness (Fig. 1b). Specifically, while T1b
patients had a better 5-year OS (36.7%) than T2 patients (29.3%), T3
patients paradoxically had a better 5-yearOS than either of these lower
T categories (45.8%). Interestingly, in AJCC 7th edition T3 patients
similarly hada better 5-yearOS (42.5%) comparedwith T2b (20.9%) and
T2a (35.7%) patients. Interestingly, as in theAJCC7th edition, AJCC8th
FIGURE 2 A) Kaplan-Meier overall survival curves stratified by AJCC 7th edition tumor staging. B) Kaplan-Meier overall survival curves
stratified by AJCC 8th edition tumor staging
TABLE 5 Comparison between the 7th and the 8th edition of the
AJCC staging systems—Validation
HR 95% CI P-value C-index
AJCC 7th editiona 0.637
I – – –
II 1.89 1.17-3.06 0.010
III 1.69 0.99-2.89 0.053
IVa 3.63 2.38-5.53 <0.001
AJCC 8th editionb 0.607
Ia – – –
Ib 6.42 0.77-53.4 0.085
II 5.89 0.77-45.0 0.088
IIIa 7.39 0.91-60.2 0.061
IIIb 16.4 2.29-117.4 0.005
aN = 515.
bN = 296.
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edition T3 patients had a higherHRof death comparedwith T1 patients
(AJCC8th ed. T3 vs. T1,HR1.6595%CI, 1.22-2.24P = 0.001) but lower
than T1b and T2 patients. As such, neither the 8th nor the 7th edition
accurately stratified patients into distinct prognostic T categories.
Moreover, the major revision that involved the addition of tumor size,
which had been omitted from the previous 7th AJCC T staging, did not
seem to addmuch additional prognostic information, as reflected in the
minimal improvement in the C-index (AJCC 7th ed., C-index 0.590 vs.
AJCC 8th ed., C-index 0.609; P = 0.39).
In addition, theoverall staginggroupsbasedon the8theditionhada
C-index of 0.607, which was actually worse than the previous 7th
edition that had a C-index of 0.637 (P = 0. 18). Of note, according to the
AJCC 8th edition, higher tumor stage was associated with an expected
generally lower 5-years OS (Fig. 2b). However, Stage II patient had an
improved 5-yearOSof 55.1%comparedwith Stage Ib patientswhohad
a 5-yearOS of 50.6%. In addition, Stage IIIa patients had a 5-year OS of
49.7%thatwas comparable toStage Ibpatients. Thesedatawere similar
when the previous 7th edition AJCC staging schema was examined.
Specifically, Stage III patients had a 5-year OS of 39.7% versus 38.8%,
and 58.8% for Stages II and I patients, respectively. In the validation
analysis of theAJCC8th edition staging system, Stage IIIa patients had a
higher risk of death versus Stage Ia patients, but the difference was not
statistically significant. This finding is in line with the comparison
betweenAJCC7thedition Stages III and I patients (P > 0.05). These data
suggest that perforation of the visceral peritoneum may not carry as
poor a prognostic impact as tumors characterized by vascular invasion.
A major shortcoming of ICC staging is that many patients do not
undergo a routine lymphadenectomy, and therefore, were classified as
Nx. To overcome this shortcoming, in part, we performed additional
analyses comparing the twoeditionsof theAJCCstaging systembasedon
lymph node status data obtained from by either preoperative radiological
imaging and/or final pathology.Of note, in this analysis, Stage IIIa patients
had a 5-year OS of 60.0% versus 35.9%, and 40.9% for Stages II and Ib
patients, respectively. In addition,AJCC8th edition Stage IIIa patients had
a higherHRof death comparedwith Sage Ib patients (AJCC8th ed. IIIa vs.
Ib, HR 1.49 95% CI, 0.97-2.30 P = 0.07), but lower than Stages Ib and II.
AJCC 8th edition staging did not seem to addmuch additional prognostic
information, as reflected in the minimal improvement in the C-index
(AJCC 7th ed., C-index 0.642 vs. AJCC 8th ed., C-index 0.667; P = 0.24).
The current study had several limitations. Due to the retrospective
nature of the study, there may have been selection and confounding
bias. However, such biases were unlikely to affect comparison of
performance of the 7th versus 8th edition staging systems. Although
the multi-institutional nature of the study was a strength, it also likely
led to heterogeneity in treatment approach.
In conclusion, although the AJCC 8th edition was able to better
stratify the risk of death of Stage III patients and T3 patients, the
revised staging system still fails to discriminate prognosis for a subset
of patients. Further improvements and refinements in the T- and
overall staging for ICC will be necessary.
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